What's Happening?
As of January 1, 2026, the first directly negotiated Medicare price for the diabetes drug Januvia has taken effect. This marks a significant milestone under the Medicare Drug Price Negotiation Program, established by the Inflation Reduction Act. The Centers
for Medicare & Medicaid Services (CMS) announced on August 15, 2024, that negotiations concluded with agreements on prices for ten selected high-spending Part D drugs, including Januvia. Merck Sharp Dohme's Januvia was among the initial drugs chosen for negotiation on August 29, 2023. In 2023, approximately 850,000 Medicare beneficiaries used Januvia, with Medicare's Part D program spending over $4 billion on the drug. While the exact negotiated price for Januvia has not been publicly disclosed, CMS mandates that participating manufacturers make these negotiated prices available to pharmacies and other dispensing entities. The negotiated price sets the maximum amount plans can pay pharmacies, plus dispensing fees, though individual beneficiary costs will vary based on their specific plan's formulary and cost-sharing arrangements.
Why It's Important?
This development is crucial for Medicare beneficiaries and the pharmaceutical industry, as it represents Medicare's first direct intervention in drug pricing. Historically, Medicare Part D plans negotiated prices with manufacturers, but the Inflation Reduction Act empowers CMS to negotiate directly for certain high-spending, single-source drugs without generic or biosimilar competition. This shift aims to reduce Medicare spending and out-of-pocket costs for beneficiaries. CMS estimated that if the negotiated prices for all ten drugs had been applied in 2023, Medicare could have saved a net $6 billion, or 22%, and beneficiaries with drug coverage could see $1.5 billion in savings in 2026. The program also requires manufacturers to pay rebates to CMS if drug prices rise faster than inflation. This new authority could set a precedent for future drug price negotiations, potentially influencing the pricing strategies of pharmaceutical companies and the accessibility of medications for millions of Americans.
What's Next?
The negotiated price for Januvia will remain in effect as long as the drug is part of the negotiation program, with CMS publishing updated prices annually based on the consumer price index. The Medicare Drug Price Negotiation Program is set to expand, with a final rule to codify the program beginning in 2029. This indicates a long-term commitment to direct price negotiations, which could encompass more drugs in subsequent rounds. The impact on beneficiaries will depend on their specific Medicare Advantage or standalone Part D plans, as these plans must include the negotiated drugs on their formularies. While the negotiated price caps what plans pay, individual out-of-pocket costs are still influenced by deductibles, copayments, and coverage phases. The ongoing implementation of the Inflation Reduction Act's drug pricing provisions will continue to reshape the landscape of prescription drug costs for Medicare enrollees.













